Related Experiment Video
Updated: May 4, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Striking growth-inhibitory effects of minocycline on human prostate cancer cell lines
Francesca Regen1, Isabella Heuser1, Irmelin Herzog1
1Department of Psychiatry, Clinical Neurobiology, Charité - Campus Benjamin Franklin, Berlin, Germany.
Objective:
To elucidate a hypothetical link between retinoic acid (RA) signaling and minocycline for targeting prostate carcinoma (PCA). RA signaling has been implicated in growth-inhibition of malignant PCA, and intracellular RA homeostasis has been investigated as a potential therapeutic target. Minocycline is a tetracycline antibiotic with pleiotropic actions in many tissues and reaches comparably high levels in human prostate tissue. Interestingly, minocycline exhibits the rare side effect of a pseudotumor cerebri, which is otherwise known to occur from vitamin A intoxication or in retinoid therapy. Therefore, we hypothesized minocycline to putatively interact with intracellular RA homeostasis in PCA.
Methods:
Using LN-CAP, DU-145, and PC-3 cell lines, effects of minocycline on microsomal RA metabolism and on cell growth were assessed in vitro.
Results:
Minocycline was identified to potently inhibit cell growth, at concentrations within the range of tissue levels readily reached under standard therapeutic conditions. In vitro inhibition experiments revealed inhibition of RA breakdown, yet only at comparably high concentrations of minocycline. Using all trans-RA, RA metabolism inhibitor liarozole, and different retinoid receptor antagonists, the putative RA-dependent effects of minocycline were further evaluated and confirmed to be independent of RA signaling.
Conclusion:
Our findings add to the growing body of evidence for the many pleiotropic actions of minocycline. In view of the striking effects of minocycline on cell growth in PCA cell lines in vitro and its relatively safe side effect profile, the use of minocycline for targeting PCA should be timely clinically evaluated.
Insights
Minocycline effectively inhibits prostate carcinoma (PCA) cell growth in vitro. While not directly impacting retinoic acid (RA) signaling, its pleiotropic effects warrant clinical evaluation for PCA treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Retinoic acid (RA) signaling is implicated in inhibiting prostate carcinoma (PCA) growth.
- Minocycline, a tetracycline antibiotic, reaches high levels in prostate tissue and has diverse effects.
- A shared side effect (pseudotumor cerebri) suggests a potential link between minocycline and RA homeostasis.
Purpose of the Study:
- To investigate a hypothetical link between retinoic acid (RA) signaling and minocycline in targeting prostate carcinoma (PCA).
- To assess minocycline's effects on RA metabolism and PCA cell growth in vitro.
Main Methods:
- Utilized LN-CAP, DU-145, and PC-3 prostate cancer cell lines.
- Assessed minocycline's impact on microsomal RA metabolism and cell growth in vitro.
- Employed all-trans-RA, liarozole, and retinoid receptor antagonists to evaluate RA-dependent effects.
Main Results:
- Minocycline demonstrated potent inhibition of PCA cell growth at therapeutic concentrations.
- Inhibition of RA breakdown by minocycline occurred only at high concentrations.
- Effects of minocycline on cell growth were confirmed to be independent of RA signaling.
Conclusions:
- Minocycline exhibits significant pleiotropic effects, including potent PCA cell growth inhibition.
- Despite RA-signaling independence, minocycline's efficacy and safety profile suggest clinical potential for PCA.
- Further clinical evaluation of minocycline for targeting prostate carcinoma is recommended.
Related Concept Videos
02:23Abnormal Proliferation
01:15Drugs that Stabilize Microtubules
02:34Inhibition of Cdk Activity
01:10Drugs that Destabilize Microtubules
02:38Mitogens and the Cell Cycle